Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

Clinical trial NCT07385079 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07385079
Sponsor: Sun Yat-sen University
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Nasopharyngeal Cancinoma (NPC)Nasopharyngeal Cancer

Start date: 2026-03-01
Primary completion: 2028-01-01
Enrollment: 412

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.